Works matching IS 11792728 AND DT 2024 AND VI 15
Results: 19
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 149, doi. 10.2147/LCTT.S485320
- By:
- Publication type:
- Article
NRG1 Fusions in NSCLC: Being eNRGy Conscious.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 143, doi. 10.2147/LCTT.S464626
- By:
- Publication type:
- Article
Adagrasib in KRYSTAL-12 has Broken the KRAS<sup>G12C</sup> Enigma Code in Non-Small Cell Lung Carcinoma.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 161, doi. 10.2147/LCTT.S490942
- By:
- Publication type:
- Article
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 129, doi. 10.2147/LCTT.S478054
- By:
- Publication type:
- Article
Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the Literature.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 123, doi. 10.2147/LCTT.S467584
- By:
- Publication type:
- Article
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 115, doi. 10.2147/LCTT.S467169
- By:
- Publication type:
- Article
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 87, doi. 10.2147/LCTT.S463429
- By:
- Publication type:
- Article
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 55, doi. 10.2147/LCTT.S455034
- By:
- Publication type:
- Article
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 75, doi. 10.2147/LCTT.S460147
- By:
- Publication type:
- Article
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 81, doi. 10.2147/LCTT.S460870
- By:
- Publication type:
- Article
"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834).
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 69, doi. 10.2147/LCTT.S461758
- By:
- Publication type:
- Article
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 41, doi. 10.2147/LCTT.S453974
- By:
- Publication type:
- Article
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 29, doi. 10.2147/LCTT.S444884
- By:
- Publication type:
- Article
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 19, doi. 10.2147/LCTT.S446878
- By:
- Publication type:
- Article
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 9, doi. 10.2147/LCTT.S446418
- By:
- Publication type:
- Article
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 19, doi. 10.2147/LCTT.S446878
- By:
- Publication type:
- Article
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact.
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 1, doi. 10.2147/LCTT.S443099
- By:
- Publication type:
- Article